Status:
COMPLETED
A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm
Lead Sponsor:
Allergan
Conditions:
Cervical Dystonia
Blepharospasm
Eligibility:
All Genders
18+ years
Brief Summary
This study is a retrospective chart review to evaluate the doses of botulinum Type A toxins BOTOX® (onabotulinumtoxinA) and Xeomin® (incobotulinumtoxinA) used for the treatment of Cervical Dystonia an...
Eligibility Criteria
Inclusion
- Confirmed primary diagnosis of idiopathic cervical dystonia or blepharospasm for at least 2 years
- Treatment with Xeomin® and BOTOX® for at least 2 years each.
Exclusion
- Having a neuromuscular junction transmission disorder or taking any medications that could affect neuromuscular junction transmission
- Previous surgical procedure involving bone or muscle for the management of cervical dystonia or blepharospasm.
Key Trial Info
Start Date :
August 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT02245958
Start Date
August 1 2015
End Date
December 1 2015
Last Update
January 8 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Colonia Roma Z.P., Mexico, 06700
2
Wakefield, United Kingdom, WF1 4DG